TrialCancer communications (London, England)2019

Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial.

Jing Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.